OPRA trial recommends continued NOM if no signs of progression in nCR patients vs. NCCN recommends repeat studies at 8 weeks, and if not converted to clinical CR, then proceed to TME.
Which recommendation do you use, and during your follow-up period, how do you address nodes when assessing response?